Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J and subsidiary pay $181M to settle landmark US case on improper marketing and advertising

This article was originally published in SRA

Executive Summary

Johnson & Johnson and its subsidiary Janssen Pharmaceuticals are paying $181 million to 36 states in the US and the District of Columbia to settle charges of improper marketing and promotion of the antipsychotics Risperdal (risperidone) and Invega (paliperidone), in the largest multi-state consumer protection-based pharmaceutical settlement in history1,2.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS116945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel